We provide end‑to‑end development and pilot manufacturing for Antibody‑Oligonucleotide Conjugates (AOCs), combining antibody engineering, linker design, oligonucleotide chemistry and bioconjugation to produce small batches suitable for toxicology and early clinical studies.
Our multidisciplinary teams, advanced equipment and closed, automated workflows shorten timelines, reduce operator exposure and simplify supply‑chain complexity so programs move confidently from discovery to clinical supply.
We coordinate antibody production, oligonucleotide synthesis, linker/payload chemistry, conjugation, analytics and fill‑finish in a single, flexible engagement to minimize transfer risk and accelerate program milestones.
We deliver stochastic lysine/cysteine approaches plus site‑specific enzymatic, glycoconjugation and click chemistries so AOC constructs can be tuned for desired homogeneity, stability and site‑specific performance.
We design cleavable and non‑cleavable linkers optimized for intracellular release and endosomal escape, support a range of oligonucleotide modalities (siRNA, antisense, gapmers, splice‑switching oligos) and can develop bespoke oligo chemistries or immune‑modulating conjugates on request.
Our analytical platform supports DAR determination, conjugation‑site confirmation, free oligonucleotide quantification, oligo integrity and nuclease/serum stability, plus functional assays for binding (EC50), internalization, endosomal escape, target knockdown/cytotoxicity and PK/PD to de‑risk candidate selection.
We run small‑scale and pilot (liter‑scale) bioconjugation with cGMP payload/linker production where required, using closed, automated processes that combine conjugation, quench/filtration and TFF in a single contained workflow to protect operators and product.
We prepare method transfer packages and scale development from lab experiments to pilot batches and larger manufacturing as programs mature, with facility designs and documentation practices to support regulatory interactions for clinical supply.
Contact our team to discuss your AOC program, request a technical capability package or arrange a feasibility discussion and timeline estimate tailored to your target, modality and desired clinical path.